Market Wrap Week 27: Resources Run Hot as Deals and Drilling Drive Gains

New Age Exploration (ASX:NAE) stole the week with a 200.00% jump after reporting a new shear-hosted gold find at Bella Prospect within its Lammerlaw project. Investors chased the stock because a fresh discovery can change the value of a small explorer very quickly, even before a formal resource is published. Talga Group (ASX:TLG) followed with a 40.00% rise after starting commercial sales of Talnode-C to Nyobolt, a key shift from promise to actual revenue. Neuren Pharmaceuticals (ASX:NEU) climbed 37.21% after a European medicines committee recommended approval for DAYBU in Rett syndrome, giving the market a clearer line to milestone payments and future royalties.

Resources did the heavy lifting

Across the board, miners and explorers set the pace. Boss Energy (ASX:BOE) rose 26.24% after meeting its FY26 uranium production target and bringing forward its Honeymoon study. Pursuit Minerals (ASX:PUR) added 25.00% as drilling began at Rio Grande Sur to test for a larger lithium brine system. Infinity Mining (ASX:IMI) gained 33.33% after test work showed almost full copper recovery from old smelter waste at Cangai, which mattered because it suggests metal may be extracted from material already sitting on site rather than from a new mine. Gold names were also well bid. Savannah Goldfields (ASX:SVG) advanced 22.22% after lifting its Red Dam resource, while Great Boulder (ASX:GBR) rose 10.00% after launching a 40,000 metre drill program at Peak Hill. Beacon Minerals (ASX:BCN) climbed 18.53% on strong Iguana drilling, and Benz Mining (ASX:BNZ) gained 8.33% as Glenburgh drilling continued to support a large gold target. In plain terms, these stocks rose because investors saw a better chance of more ounces, longer mine lives or both.

Deals got done, but not every buyer won applause

Corporate activity stayed busy. Alcoa Corporation (ASX:AAI) agreed to buy South32’s bauxite, alumina and aluminium assets for $4.1 billion upfront, plus up to $750 million linked to commodity prices. The deal is meant to add scale and lock in more supply. Yet AAI still finished the week 4.19%, a sign some investors worried about the size of the cheque, the wait until a first-half 2027 close, or the work needed to blend the assets together. Other buyers had a warmer reception. Ampol (ASX:ALD) rose 4.05% after completing its $1.165 billion EG Australia purchase. Tasmea (ASX:TEA), despite finishing 6.90% lower for the week, completed its $254 million Maxim deal and said the electrical division should supply more than half of FY27 earnings before interest, tax and amortisation, which is a way of measuring profit from day-to-day operations. Forrestania Resources (ASX:FRS) was one of the busiest small-cap stories after agreeing to buy the Edna May Gold Hub and raising A$310 million, ending the week 5.88%. Even there, the stock slipped after reopening, showing that early gains evaporated once traders weighed the scale of the capital raise.

Healthcare and tech delivered cleaner stories

Healthcare winners were driven by specific events that were easy for investors to price. Neuren’s rise came after a positive European opinion for DAYBU. Telix Pharmaceuticals (ASX:TLX) gained 10.11% after the FDA backed the next part of its late-stage prostate cancer trial, meaning the study design now has a clearer route in the US. Orthocell (ASX:OCC) slipped 0.66% for the week despite a Thailand distribution deal, while Aroa Biosurgery (ASX:ARX) fell 3.39% even after reporting strong revenue growth. In both cases, the news was positive, but the buying was not strong enough to hold the shares higher through the week. Technology names were mixed. Enlitic (ASX:ENL) rose 20.00% after locking in a A$15 million raising and a debt conversion, because the market now has a clearer picture of how the company funds its software rollout. Echo IQ (ASX:EIQ) added 3.77% on a large heart imaging data deal. Archer Materials (ASX:AXE) dropped 11.11% even after announcing a three-year agreement with IonQ, a reminder that investors still want proof that a high-profile partnership can turn into sales or a finished product.

What the gaps said

Several sharp reopenings told two different stories. Some names held their jump or added to it. Genesis Minerals (ASX:GMD) rose 16.70% and kept pushing after meeting guidance and advancing Tower Hill. Sunstone Metals (ASX:STM) gained 4.88% for the week, but was much stronger from its reopening level after DGR Global backed its placement. Karoon Energy (ASX:KAR) rose 10.71% as production returned at Baúna and buyback plans gave investors another reason to stay in the stock. Others could not keep the early excitement. Brazilian Critical Minerals (ASX:BCM) still ended up 17.02%, but only added modestly after its reopening despite a strong feasibility study. KGL Resources (ASX:KGL) fell 13.87% after a large equity raising to fund Jervois, which likely worried holders about dilution, meaning their share of the company shrinks when more stock is issued. Greatland Resources (ASX:GGP) closed 2.89% for the week and sank harder from its reopening level, even though ore reserves grew strongly. That points to profit-taking, which simply means some traders chose to lock in gains rather than wait for the next update. More broadly, the week rewarded companies that could point to one concrete step forward: first sales, a regulator’s approval, funded drilling, a bigger resource, or a signed contract. It was less forgiving where the good news came with a large capital raising, a long wait for completion, or a result that still needs a lot of work before it turns into cash.